Longevity & AgingFederal Program Selects LNS8801 to Test If New Drug Extends Lifespan
A drug called LNS8801, developed by Linnaeus Therapeutics, has been chosen for the National Institute on Aging's Interventions Testing Program — one of the most rigorous independent drug-testing programs for longevity in the US. The drug works by activating a receptor called GPER, which is linked to estrogen signaling. It will be tested in mice to see if it can extend lifespan and slow age-related decline. Separately, a $22 million federal ARPA-H contract will fund research into whether LNS8801 preserves physical mobility, cognition, and vitality in aging. The drug has already shown safety in human cancer trials, making it a credible candidate for broader aging research.
